SciELO - Scientific Electronic Library Online

 
vol.78 número6Características clínicas y epidemiológicas de la COVID-19 en niños: experiencia en dos centros hospitalariosConstrucción y validación de la escala de factores y actitudes asociados con las prácticas de crianza parental de niños con nacimiento de alto riesgo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Boletín médico del Hospital Infantil de México

versión impresa ISSN 1665-1146

Bol. Med. Hosp. Infant. Mex. vol.78 no.6 México nov./dic. 2021  Epub 29-Sep-2021

https://doi.org/10.24875/bmhim.20000231 

Research articles

Antibiotherapy at birth in very low birth weight infants before and after the use of interleukin 6 as an infectious biomarker in a tertiary level unit

Antibioterapia al nacimiento en recién nacidos de muy bajo peso antes y después del uso de interleucina 6 como marcador de infección en una unidad de nivel III

Sonia Lareu-Vidal1  * 

Gonzalo Solís-Sánchez1 

María Caunedo-Jiménez1 

Silvia Martín-Ramos1 

Marta Costa-Romero2 

Belén Fernández-Colomer1 

1Servicio de Neonatología, Hospital Universitario Central de Asturias, Oviedo

2Servicio de Neonatología, Hospital de Cabueñes, Gijón. Asturias, Spain


Abstract

Background:

Neonatal sepsis is a condition with high mortality and morbidity that contributes to high rates of antibiotic therapy at birth. In addition, very low birth weight newborns (VLBWN) are particularly vulnerable. Interleukin 6 (IL-6) seems to be an early and effective marker that could help a better selection of patients to be treated. This study aimed to evaluate the use of antibiotics in the first 72 hours of life in VLBW infants before and after using IL-6 as an infection marker. Also, we wanted to analyze the differences in morbidity and mortality during admission and other factors associated with the decision to start antibiotic treatment.

Methods:

We conducted a cohort retrospective study. We included VLBWN born in our hospital or admitted before 72 hours of life in two two-year periods (2007-2008 and 2011-2012).

Results:

Antibiotics use during the first 72 hours of life was analyzed as the primary variable, which was reduced by 20% on the second period (p = 0.002). Regarding the analysis of secondary variables, we found no significant differences in mortality during hospital admission and the incidence of nosocomial sepsis, enterocolitis, or invasive fungal infection. The multivariate analysis indicated extreme prematurity and the study group as the most strongly related factors to the start of antibiotic therapy.

Conclusions:

IL-6 was a useful marker of infection to reduce the use of antibiotic therapy in VLBW infants without increasing mortality.

Keywords Interleukin 6; Neonatal sepsis; Antibiotics; Very low-birth weight newborns

Resumen

Introducción:

La sepsis neonatal es una patología con altas mortalidad y morbilidad, lo cual contribuye a las altas tasas de antibioticoterapia al nacimiento. Los recién nacidos de muy bajo peso (RNMBP) son especialmente vulnerables. La interleucina 6 (IL-6) parece ser un marcador precoz y eficaz que podría ayudar a una mejor selección de los pacientes. El objetivo de este estudio fue evaluar el uso de antibióticos en las primeras 72 horas de vida en los RNMBP antes y después de utilizar IL-6 como marcador de infección; en segundo lugar, analizar las diferencias en la morbilidad y la mortalidad durante el ingreso, y estudiar la presencia de otros factores asociados con la decisión de iniciar un tratamiento antibiótico.

Métodos:

Se llevó a cabo un estudio de cohortes en el que se incluyeron los RNMBP nacidos en nuestro hospital o admitidos antes de las 72 horas de vida en dos periodos de 2 años (2007-2008 y 2011-2012).

Resultados:

Como variable principal se analizó el uso de antibióticos en las primeras 72 horas de vida, que se redujo casi un 20% en el segundo periodo (p = 0.002). En cuanto a las variables secundarias, no se detectaron diferencias significativas en la mortalidad durante el ingreso ni en la incidencia de sepsis nosocomial, enterocolitis o infección fúngica invasiva. El análisis multivariado señaló la extrema prematuridad y el grupo de estudio como los factores más estrechamente relacionados con el inicio de la antibioticoterapia.

Conclusiones:

La IL-6 fue un marcador de infección útil para reducir el uso de antibioticoterapia al nacimiento en los RNMBP, sin aumentar la mortalidad.

Palabras clave Interleucina 6; Sepsis neonatal; Antibióticos; Recién nacido de muy bajo peso

Introduction

Neonatal sepsis of vertical transmission constitutes one of the most significant challenges for neonatologists due to its high morbidity and mortality and difficult diagnosis1.

This pathology affects approximately 9-11 per 1000 very low birth weight newborns (VLBWN), and the mortality can be as high as 8%2,3. Also, the pathogenesis is more complicated in preterm infants4-6. Intraamniotic infection probably starts before labor and might be the cause—not the consequence—of premature rupture of membranes. In addition, other causes of immune-mediated inflammation may promote rupture and trigger labor. Therefore, it is implied that the same infectious risk factors do not have the same weight on both populations7,8.

Regarding diagnosis, symptomatology is not specific and is common to other pathologies of prematurity: infection markers are not sensitive and specific enough, and blood culture, considered the gold standard, has a mediocre diagnostic yield, in addition to a long waiting period9,10. Furthermore, during the first days of life, the ongoing metabolic, hormonal, and immunological processes complicate determining the standard values of these markers.

These reasons, such as the often fulminant presentation of this type of sepsis and the great difficulty in its diagnosis, often lead to initiate probabilistic antibiotic treatment at birth and prolong it despite negative cultures11-13. However, the consequences are not trivial.

The use of antibiotics in the neonatal period leads to a decrease in the biodiversity of the intestinal microbiota, among other things, favoring the appearance of pathogenic organisms and delaying the usual colonization of the gastrointestinal tract14-16. In extremely premature infants, this microbiota modification implies an increased risk of late sepsis, ulcerative-necrotizing enterocolitis, and invasive fungal infection17-19.

Therefore, the challenge is to reduce the use of antibiotics without compromising this vulnerable population. One of the means of improvement to achieve this objective is identifying new biological markers of infection. These include interleukins 6, 8, and 10, nCD64, alarmins, and IP-10, among others20-23.

The use of interleukin 6 (IL-6) as a marker was introduced in our Unit in 2009. IL-6 is a pleiotropic interleukin of the innate immunity produced by different cell types and recognized as the central mediator of the acute phase response24. Also, IL-6 has markedly early kinetics in infections. Importantly, there is no physiological elevation of IL-6 in newborns. Numerous studies support its use as an early marker of sepsis, particularly associated with other markers25-36.

This study aimed to determine the use of antibiotics during the first 72 hours in VLBWN and analyze whether the introduction of IL-6 as a marker of sepsis reduced this use37. As secondary objectives, we wanted to compare the morbidity and mortality of both groups during admission and to study other possible factors associated with initiating antibiotic treatment.

Methods

We conducted a retrospective cohort study. The first cohort corresponded to a period before IL-6 was used as a marker of sepsis in the service (group I or Pre IL-6). The second cohort corresponded to a period after introducing IL-6 (group II or Post IL-6).

We included patients admitted from January 1, 2007, to December 31, 2008 (group I) and from January 1, 2011, to December 31, 2012 (group II). This study was a single-center study in a level IIIb unit (Neonatology Department of the Hospital Universitario Central de Asturias, Spain).

Preterm newborns with birth weight < 1500 g born in our hospital or hospitalized during the first 72 hours of life were selected. We considered the day of admission as the moment of enrollment in the cohort (Figure 1).

Figure 1 Flow chart of patients from two study periods. IL-6, interleukin 6. 

The primary outcome variable was the administration of antibiotic therapy during the first 72 hours of life. The secondary outcome variables were those related to morbidity during admission: nosocomial sepsis, necrotizing enterocolitis, invasive fungal infection, days of hospital stay, and mortality.

We also collected general variables and those related to the diagnosis and treatment of early sepsis (C-reactive protein (CRP) and IL-6 levels in the admission blood test, blood culture results, antibiotic treatment, and duration) to characterize both populations. IL-6 levels at birth are expressed in pg/mL. In group I, the cut-off value in the first 72 hours was 150 pg/mL, and in group II, 300 pg/mL38,39.

We also collected data on potentially effect-modifying variables such as risk factors for infection or gestational age. Discharge reports, hospitalization clinical course, and nursing charts were used for data collection through the hospital's information software (Cerner Millenium).

Qualitative variables were expressed as percentages. Normal quantitative variables were reported as the mean with a 95% confidence interval (95% CI). In the case of the Apgar test, the median and interquartile ranges were used. As the groups are sufficiently large, we assumed that the distribution of the means followed a normal distribution according to the central limit theorem.

When considered relevant, percentages were compared using the χ2 test and the odds ratio (OR) with its confidence interval. The Student's t-test was used to compare quantitative variables and the Mann-Whitney's U-test for the Apgar test.

A binary logistic regression was performed (Wald backward stepwise method with PIN 0.05 and POUT 0.10) to determine which variables had a statistically significant effect after the previous analysis. The dependent variable was the antibiotic treatment, and the independent variables were prolonged rupture of membranes (> 18 h), gestational age (< 28 weeks), spontaneous prematurity, and the study group (I or II).

Statistical analysis was performed with SPSS-17 and R packages.

The Regional Ethics Committee (CEIP-Comité de Ética en Investigación de Asturias) approved this protocol.

Results

General characteristics of both groups

We had two groups of 102 and 98 patients (group I and II, respectively). Table 1 shows the general variables of both groups. In group I, the mean gestational age was 28 weeks (95% CI 28.4-29.3), the mean birth weight was 1086 g (95% CI 1034-1139), the sex distribution was almost equal (52% male), and the median Apgar 7 and 8 at 1 and 5 min, respectively. In group II, the mean gestational age was 29 weeks (95% CI 28.3-29.6), mean birth weight 1085 g (95% CI 1030-1140), 53% were male, and median Apgar 7 and 9 at 1 and 5 min, respectively. No significant differences were found between groups regarding these variables.

Table 1 Comparative analysis of initial characteristics of patients in the studied groups 

Characteristics of the patients Group I (n = 102) Jan 2007-Dec 2008 n (%) Group II (n = 98) Jan 2011-Dec 2012 n (%) p-values
Gestational age (weeks)* 28 (28.4-29.3) 29 (28.3-29.6) 0.738
Birth weight (g)* 1086 (1034-1139) 1085 (1030-1140) 0.983
Spontaneous prematurity 57 (55.9%) 62 (63.3%) 0.288
Rupture of membranes (> 18 h) 7 (6.9%) 20 (20.4%) 0.005
Sex
Male 53 (52%) 52 (53.1%)
Female 49 (48%) 46 (46.9%)
Multiple birth 40 (39%) 38 (39%) 0.958
Chorioamnionitis 3 (2.9%) 8 (8.2%) 0.105
Type of delivery
Cesarean section 77 (75.5%) 60 (61.2%) 0.025
Normal 25 (24.5%) 34 (34.7%)
Instrumental vaginal delivery 0 4 (4.1%)
Gestation obtained through in vitro fertilization 8 (7.8%) 23 (23.5%) 0.002
Prenatal corticosteroid therapy
Partial 26 (25.5%) 46 (46.9%) 0.005
Complete 61 (59.8%) 40 (40.8%)
Maternal antepartum antibiotic therapy 16 (16.3%) 38 (39.6%) 0.001
Apgar 1 min** 7 (4) 7 (4) 0.548
Apgar 5 min** 8 (2) 9 (2) 0.883
Intubation in the delivery room 41 (41.8%) 33 (32.4%) 0.132
Received surfactant at some point 55 (53.9%) 52 (53%) 0.972
Diagnosis of hyaline membrane disease 54 (52.9%) 56 (57.1%) 0.492
Persistent ductus arteriosus 20(19.6%) 33 (33.7%) 0.030
Pharmacological treatment of persistent ductus arteriosus (ibuprofen) 14 (13.7%) 15 (15.3%) 0.706
CRP (mg/dL)* 0.55 (0.39-0.72) 0.10 (0.06-0.15) 0.001
IL-6 > 150 pg/mL 18 (37.8%)
IL-6 > 300 pg/mL 15 (31%)
Inotropes hypotension 22 (21.6%) 22 (22.4%) 0.382
Nasal CPAP/MV at 28 days of life 10 (9.8%) 13 (13.2%) 0.707

CI, confidence interval; CPAP, continuous positive airway pressure; CRP, C-reactive protein; IL-6, interleukin 6; IQR, interquartile range; MV, mechanical ventilation.

*Mean (95%CI);

**Median (IQR).

We found significant differences between the groups (p = 0.025) regarding the birth route: 24.5% of normal deliveries and 75.5% of cesarean sections in group I versus 34.7% of normal deliveries, 60% of cesarean sections, and 4.1% of instrumental delivery in group II.

Concerning infectious risk factors, no statistically significant differences were found in the percentage of spontaneous prematurity or chorioamnionitis. However, significant differences in prolonged rupture of membranes were observed (6.9% in group I vs. 20.4% in group II).

Regarding the antibiotherapy, 76.5% of patients received antibiotics in the first 72 hours of life in group I versus 57% in group II. This difference was statistically significant (p = 0.004). When we analyzed the percentage of antibiotic therapy in patients with sterile blood culture, the difference was 17%, but not statistically significant (75% group I and 57.7% group II; p = 0.052) (Table 2). We were able to collect this variable in all preterm infants except for four patients from group II. Figure 2 shows the percentage of antibiotic therapy and antibiotic therapy in patients with sterile blood culture by study group.

Table 2 Comparative analysis of the primary and secondary outcome variables of both groups 

Primary and secondary outcome variables Group I Jan 2007-Dec 2008 (n = 102) n (%) Group II Jan 2011-Dec 2012 (n = 98) n (%) p- values
Antibiotic therapy in the first 72 h of life 78 (76.5%) 56 (57.1%) 0.004
Antibiotic therapy in the first 72 h of life in patients with sterile blood culture 69 (75%) 52 (57.7%) 0.052
Result of blood culture at birth
Gram-negative 4 (3.9%) 1 (1%) 0.348
Coagulase-negative Staphylococcus 2 (1.9%) 2 (2%)
Another microorganism 4 (3.9%) 1 (1%)
Sterile 92 (90%) 90 (91.8%)
Invasive fungal infection 4 (3.9%) 0 0.066b
Exitus during admission 22 (21.6%) 21 (21.4%) 0.981
Antibiotic cycles
Median (IQR) 1 (1) 1 (5) 0.041
Median (95% CI) 1.5 (1.3-1.7) 1.25 (1.0-1.4) 0.086
Blood culture resulta n = 50 n = 44
Gram negative 18 (36%) 9 (20%) 0.119
Coagulase negative Staphylococcus 15 (30%) 23 (51%)
Another microorganism 5 (10%) 6 (13%)
Sterile 12 (24%) 7 (16%)
In-hospital stay days in survivorsc
Mean (95%CI) 89.8 (66.7-112.8) 51.1 (44.7-57.5) 0.002

aBlood culture extracted in the first episode of nosocomial sepsis;

bFisher's exact test;

cExcluding those who died in the first week of life.

CI, confidence interval; IQR, interquartile range.

Figure 2 Percentage of antibiotic therapy by study group and percentage of antibiotic therapy in patients with sterile blood culture by study group. Comparison of the percentage of antibiotic therapy between both groups, p = 0.002. Comparison of the percentage of antibiotic therapy between both groups in patients with sterile blood culture, p = 0.006. 

Mean CRP at birth was 0.55 mg/dL (95% CI 0.39-0.72) in group I and 0.10 mg/dL (95% CI 0.06-0.15) in group II (p = 0.001). We were able to collect IL-6 levels in 79 of 98 patients. The mean IL-6 at birth was 501 pg/mL (95% CI -52-1054), and the median was 36 pg/mL. Both markers do not appear to be correlated strongly with CRP at birth (Spearman's correlation coefficient of 0.3) in most patients.

As for the duration of antibiotic treatment, no significant differences were observed in the mean and median between groups (group I, mean 5.9 days (95% CI 5.4-6.5); median of 5.5; group II, mean 5.3 days (95% CI 4.7-5.9); median of 5).

The antibiotics used in both groups were ampicillin and an aminoglycoside in > 95% of the patients. In group I, vancomycin was used in three patients and cefotaxime in one patient. In group II, vancomycin was used in two patients and meropenem in one patient with abdominal surgical pathology (neonatal appendicitis).

Regarding the results of blood cultures collected at birth, 90.2% were sterile in group I and 95.9% in group II (p = 0.348). Of the remaining, 1.9% of group I and 2 % of group II were positive for coagulase-negative Staphylococcus, 3.9% of group I and 1% of group II were positive for a Gram-negative microorganism, and 3.9% of group I and 1% in group II were positive for another microorganism.

In the second study period, we analyzed the percentage of patients who had an IL-6 value above the cut-off level (within the group that had received antibiotics) to find out the importance of IL-6 in the decision to initiate an antibiotic treatment: 37.8% had an IL-6 > 150 pg/mL and 31% had an IL-6 > 300 pg/mL (Table 1). The percentages of patients with IL-6 above and below the cut-off values (150 pg/mL and 300 pg/mL) in the group of patients receiving antibiotic treatment are shown in Figures 3 and 4.

Figure 3 Percentage of patients with IL-6 above and below the cut-off value (150 pg/mL) in the group of patients receiving antibiotic therapy. IL-6, interleukin 6. 

Figure 4 Percentage of patients with IL-6 above and below the cut-off value (300 pg/mL) in the group of patients receiving antibiotic therapy. IL-6, interleukin 6. 

Table 2 shows the variables related to evolution during admission and mortality. No statistically significant differences were found in the percentage of nosocomial sepsis (first episode), necrotizing enterocolitis, invasive fungal infection, or mortality. However, all were slightly higher in group I. In-hospital stay in those who survived beyond the first week of life was significantly longer in group I patients (mean 89.8 days vs. 51.1 days, p = 0.002). The median number of antibiotic cycles was 1.5 (95% CI 1.3-1.7) in group I and 1.25 (95% CI 1.0-1.4) in group II.

The result of the blood culture obtained during the first episode of nosocomial sepsis was documented: 24% were sterile in group I and 16% in group II (p = 0.304). When analyzing those positive for a Gram-negative microorganism, we found 36% in group I and 20% in group II.

Table 3 shows the bivariate analysis between the patients who received antibiotics (groups I and II) and those who did not. Lower gestational age, lower birth weight, spontaneous prematurity, chorioamnionitis, and belonging to study group I were more frequent in the patients receiving antibiotics, with statistically significant differences.

Table 3 Comparative analysis of variables related to the risk of developing sepsis of vertical transmission between the patients who received antibiotics in the first 72 hours of life and those who did not receive antibiotics 

Variables related to risk Patients receiving antibiotic therapy in the first 72 h of life (n = 129) n (%) Patients NOT receiving antibiotic therapy in the first 72 h of life (n = 71) n (%) p- values
Gestational age (weeks)* 27.9 (27.5-28.4) 30.9 (30.4-31.5) < 0.001
Weight (g)* 1022 (978-1067) 1215 (1155-1275) < 0.001
Spontaneous prematurity 96 (71.6%) 23 (34.8%) < 0.001
Chorioamnionitis 11 58.2%) 0% 0.017
Rupture of membranes > 18 h 22 (16.4%) 5 (7.6%) 0.085
Belonging to study group I 78 (58.2%) 24 (36.4%) 0.004

*Mean (95%CI).

CI, confidence interval.

The results of the multivariate analysis are shown in Table 4. Spontaneous prematurity would multiply the risk of receiving antibiotics by 3, extreme prematurity by 16, and belonging to study group I by 4.

Table 4 Binary logistic regression. Dependent variable: initiation antibiotic treatment in the first 72 hours of life in very-low-birth-weight infants 

Risk factors B Significance OR 95%CI
Inferior Superior
Spontaneous prematurity 1.11 0.002 3.28 1.52 7.04
Study group 1.44 < 0.001 4.22 1.96 9.08
Gestational age < 28 weeks 2.80 < 0.001 16.59 4.65 59.23
Constant 1.28 < 0.001 0.27

CI, confidence interval; OR, odds ratio.

Discussion

The use of antibiotics during the first 72 hours of life in VLBWN reached 76.5% of the patients in our Unit, similar to those found in the literature. After implementing IL-6 testing as a biological marker of sepsis in 2009, we observed a 20% reduction in antibiotic therapy. This reduction was almost maintained in the group of patients with negative blood cultures. We have specified this last point because it seems that the negative consequences of this antibiotic treatment would be more pronounced in preterm infants with sterile blood cultures40. These data confirm our working hypothesis; however, due to the type of study performed, we cannot conclude that this decrease is exclusively due to the use of IL-6. To analyze the question in more detail, we have examined some of the factors related to initiating antibiotic treatment. As already discussed, this decision is based on three pillars that are not easy to interpret in preterm infants: clinical features, clinical risk factors, and biological markers of infection.

Regarding the general data that can determine the status of the newborn after delivery (gestational age, weight, Apgar, and others), both groups had similar characteristics.

Although CRP levels at birth differed significantly, no clinical differences were observed. There is no single cut-off value accepted worldwide, but the figures in both groups are clearly below levels suggestive of sepsis. As procalcitonin is only used to diagnose nosocomial sepsis in our department, it was not included in the analysis.

Regarding clinical risk factors, neonatologists do not usually distinguish between term and preterm newborns, although the pathophysiology in both conditions is not the same. Our data support this fact, as prolonged rupture of membranes, one of the most important infectious risk factors in the term newborn, predominates significantly in the second study period without a higher percentage of confirmed sepsis. In these cases, other non-infectious causes of stress might be leading to the initiation of labor and rupture of membranes41,42.

Following the reasoning of the document published by the American Academy of Pediatrics in 2018, preterm infants with the lowest risk of presenting an early bacterial neonatal infection are those born by cesarean section and those born due to induced prematurity6. However, we found a higher percentage of spontaneous prematurity and vaginal deliveries in group II.

We can cite two reasons that might play a role: the change in the Director of Obstetrics in 2010, who clearly wanted to reduce the percentage of cesarean sections, and the progressive change in obstetrics practices—better control of pregnant women and a limitation of the indications for cesarean section in the case of premature delivery43,44. After analyzing these items in our sample, no other variable was found that clearly explained the decrease in the use of antibiotic treatment in the second period, except for IL-6.

We also performed a binary logistic regression to determine which variables were significantly related. Our results were consistent with other studies6: gestational age < 28 weeks would multiply the risk of receiving antibiotics by 16, spontaneous prematurity (versus induced prematurity) by 3, and belonging to group I of the study by 4. It should be noted that the percentage of extreme prematurity in both samples was similar (35.3% in group I and 37.7% in group II).

Regarding the evolution during admission, we found no statistically significant differences in the percentage of nosocomial sepsis, invasive fungal infection, necrotizing enterocolitis, or mortality. However, the mean in-hospital stay was significantly longer in group I. The complexity of the patients does not seem to justify this fact a priori since it was similar in both groups. Conversely, no significant changes were identified between the two periods in the management protocols of these patients in our Unit, especially in the management of neonatal sepsis of vertical transmission or those aspects related to the incidence of nosocomial sepsis, such as catheter insertion, its duration, and the type of feeding, among others.

After analyzing the clinical and paraclinical variables associated with the decision to initiate antibiotic treatment, it seems that the use of IL-6 as an early marker of sepsis in very low birth weight preterm newborns significantly reduces the use of antibiotics in the first 72 hours of life. It is more difficult to conclude subsequent evolution, but it seems that morbidity, length of hospital stay, and mortality are lower in the second period.

References

1. Hornik CP, Fort P, Clark RH, Watt K, Benjamin DK Jr, Smith PB, et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev. 2012;88(Suppl 2):S69-S74. [ Links ]

2. López Sastre JB, Coto Cotallo GD, Fernández Colomer B;Grupo de Hospitales Castrillo. Neonatal sepsis of vertical transmission:an epidemiological study from the “Grupo de Hospitales Castrillo“. J Perinat Med. 2000;28:309-15. [ Links ]

3. Schrag SJ, Farley MM, Petit S, Reingold A, Weston EJ, Pondo T, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics. 2016;138:e20162013. [ Links ]

4. Burdet J, Dominguez Rubio AP, Salazar AI, Ribeiro ML, Ibarra C, Franchi AM. Inflammation, infection and preterm birth. Curr Pharm Des. 2014;20:4741-8. [ Links ]

5. Peng CC, Chang JH, Lin HY, Cheng PJ, Su BH. Intrauterine inflammation, infection, or both (Triple I):a new concept for chorioamnionitis. Pediatr Neonatol. 2018;59:231-7. [ Links ]

6. Puopolo KM, Benitz WE, Zaoutis TE, Committee on Fetus and Newborn, Committee on Infectious Diseases. Management of neonates born at ≤34 6/7 weeks'gestation with suspected or proven early-onset bacterial sepsis. Pediatrics. 2018;142:e20182896. [ Links ]

7. Puopolo KM, Draper D, Wi S, Newman TB, Zupancic J, Lieberman E, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics. 2011;128:e1155-63. [ Links ]

8. Puopolo KM, Mukhopadhyay S, Hansen NI, Cotten CM, Stoll BJ, Sanchez PJ, et al. Identification of extremely premature infants at low risk for early-onset sepsis. Pediatrics. 2017;140:e20170925. [ Links ]

9. Benitz WE. Adjunct laboratory tests in the diagnosis of early-onset neonatal sepsis. Clin Perinatol. 2010;37:421-38. [ Links ]

10. Mussap M. Laboratory medicine in neonatal sepsis and inflammation. J Matern Fetal Neonatal Med. 2012;25(Suppl 4):32-4. [ Links ]

11. Cordero L, Ayers LW. Duration of empiric antibiotics for suspected early-onset sepsis in extremely low birth weight infants. Infect Control Hosp Epidemiol. 2003;24:662-6. [ Links ]

12. Oliver EA, Reagan PB, Slaughter JL, Buhimschi CS, Buhimschi IA. Patterns of empiric antibiotic administration for presumed early-onset neonatal sepsis in neonatal intensive care units in the United States. Am J Perinatol. 2017;34:640-7. [ Links ]

13. Flannery DD, Ross RK, Mukhopadhyay S, Tribble AC, Puopolo KM, Gerber JS. Temporal trends and center variation in early antibiotic use among premature infants. JAMA Netw Open. 2018;1:e180164. [ Links ]

14. Zwittink RD, Renes IB, van Lingen RA, van Zoeren-Grobben D, Konstanti P, Norbruis OF, et al. Association between duration of intravenous antibiotic administration and early-life microbiota development in late-preterm infants. Eur J Clin Microbiol Infect Dis. 2018;37:475-83. [ Links ]

15. Zwittink RD, van Zoeren-Grobben D, Renes IB, van Lingen RA, Norbruis OF, Martin R, et al. Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment. BMC Pediatr. 2020;20:195. [ Links ]

16. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe. 2015;17:553-64. [ Links ]

17. Flannery DD, Dysart K, Cook A, Greenspan J, Aghai ZH, Jensen EA. Association between early antibiotic exposure and bronchopulmonary dysplasia or death. J Perinatol. 2018;38:1227-34. [ Links ]

18. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sánchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009;123:58-66. [ Links ]

19. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. 2011;159:720-5. [ Links ]

20. Boskabadi H, Maamouri G, Tavakol Afshari J, Mafinejad S, Hosseini G, Mostafavi-Toroghi H, et al. Evaluation of serum interleukins-6, 8 and 10 levels as diagnostic markers of neonatal infection and possibility of mortality. Iran J Basic Med Sci. 2013;16:1232-7. [ Links ]

21. Ng PC, Li K, Chui KM, Leung TF, Wong RPO, Chu WCW, et al. IP-10 is an early diagnostic marker for identification of late-onset bacterial infection in preterm infants. Pediatr Res. 2007;61:93-8. [ Links ]

22. Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. Intensive Care Med. 2007;33:1025-32. [ Links ]

23. Küster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, et al. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet. 1998;352:1271-7. [ Links ]

24. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1-20. [ Links ]

25. Sun B, Liang LF, Li J, Yang D, Zhao XB, Zhang KG. A meta-analysis of interleukin-6 as a valid and accurate index in diagnosing early neonatal sepsis. Int Wound J. 2019;16:527-33. [ Links ]

26. Ebenebe CU, Hesse F, Blohm ME, Jung R, Kunzmann S, Singer D. Diagnostic accuracy of interleukin-6 for early-onset sepsis in preterm neonates. J Matern Fetal Neonatal Med. 2019;34:253-8. [ Links ]

27. Hu J, Du PF, Bei DD. [Diagnostic value of interleukin 6 for neonatal sepsis:a Meta analysis]. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17:1176-82. [ Links ]

28. Shahkar L, Keshtkar A, Mirfazeli A, Ahani A, Roshandel G. The role of IL-6 for predicting neonatal sepsis:a systematic review and meta-analysis. Iran J Pediatr. 2011;21:411-7. [ Links ]

29. Doellner H, Arntzen KJ, Haereid PE, Aag S, Austgulen R. Interleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr. 1998;132:295-9. [ Links ]

30. Mirzarahimi M, Barak M, Eslami A, Enteshari-Moghaddam A. The role of interleukin-6 in the early diagnosis of sepsis in premature infants. Pediatr Rep. 2017;9:7305. [ Links ]

31. Cobo T, Kacerovsky M, Andrys C, Drahosova M, Musilova I, Hornychova H, et al. Umbilical cord blood IL-6 as predictor of early-onset neonatal sepsis in women with preterm prelabour rupture of membranes. PLoS One. 2013;8:e69341. [ Links ]

32. Procianoy RS, Silveira RC. The role of sample collection timing on interleukin-6 levels in early-onset neonatal sepsis. J Pediatr (Rio J). 2004;80:407-10. [ Links ]

33. Steinberger E, Hofer N, Resch B. Cord blood procalcitonin and interleukin-6 are highly sensitive and specific in the prediction of early-onset sepsis in preterm infants. Scand J Clin Lab Invest. 2014;74:432-6. [ Links ]

34. Beceiro Mosquera J, Sivera Monzo CL, Oria de Rueda Salguero O, Olivas López de Soria C, Herbozo Nory C. Utilidad de un test rápido de interleuquina-6 sérico combinado con proteína C reactiva para predecir la sepsis en recién nacidos con sospecha de infección. An Pediatr. 2009;71:483-8. [ Links ]

35. Celik IH, Demirel G, Uras N, Oguz SS, Erdeve O, Dilmen U. Función de la concentración sérica de interleucina 6 y proteína C-reactiva para diferenciar la etiología de la septicemia neonatal. Arch Argent Pediatr. 2015;113:534-43. [ Links ]

36. Costa RM. Interleukina-6 como marcador diagnóstico de sepsis neonatal [thesis]. Asturias:Universidad de Oviedo;2010. [ Links ]

37. Vignally P, Gentile S, Bongiovanni I, Sambuc R, Chabot J-M. [Évaluation des pratiques professionnelles du médecin :historique de la démarche en France]. SantéPublique. 2007;19:81-6. [ Links ]

38. Prieto B, Miguel D, Costa M, Coto D, Álvarez FV. New quantitative electrochemiluminescence method (ECLIA) for interleukin-6 (IL-6) measurement. Clin Chem Lab Med. 2010;48:835-8. [ Links ]

39. Celik İH, Demirel FG, Uras N, Oguz SS, Erdeve O, Biyikli Z, et al. What are the cut-off levels for IL-6 and CRP in neonatal sepsis?J Clin Lab Anal. 2010;24:407-12. [ Links ]

40. Ting JY, Synnes A, Roberts A, Deshpandey A, Dow K, Yoon EW, et al. Association between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants without culture-proven sepsis or necrotizing enterocolitis. JAMA Pediatr. 2016;170:1181-7. [ Links ]

41. Romero R, Dey SK, Fisher SJ. Preterm labor:one syndrome, many causes. Science. 2014;345:760-5. [ Links ]

42. Ofman G, Vasco N, Cantey JB. Risk of early-onset sepsis following preterm, prolonged rupture of membranes with or without chorioamnionitis. Am J Perinatol. 2016;33:339-42. [ Links ]

43. Simões R, Cavalli RC, Bernardo WM, Salomão AJ, Baracat EC. Cesarean delivery and prematurity. Rev Assoc Med Bras (1992). 2015;61:489-94. [ Links ]

44. Sentilhes L, Sénat M-V, Ancel P-Y, Azria E, Benoist G, Blanc J, et al. Recommandations pour la pratique clinique:prévention de la prématuritéspontanée et de ses conséquences (hors rupture des membranes) —Texte des recommandations (texte court). J Gynécologie Obstétrique Biol Reprod. 2016;45:1446-56. [ Links ]

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on patient data publication.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article requested by their Ethics Committee.

FundingNone.

Received: July 28, 2020; Accepted: April 09, 2021

* Correspondence: Sonia Lareu-Vidal E-mail: sonia.lareu.vidal@gmail.com

Conflicts of interest

The authors declare no conflict of interest with pharmaceutical companies.

Creative Commons License Instituto Nacional de Cardiología Ignacio Chávez. Published by Permanyer. This is an open access article under the CC BY-NC-ND license